Brief: Mustang Bio Announces Exclusive Worldwide License Agreement with Leiden University Medical Centre
10/11/2021 14:57
Nov 10 (Reuters) - Fortress Biotech Inc FBIO.O :
* MUSTANG BIO ANNOUNCES EXCLUSIVE WORLDWIDE LICENSE
AGREEMENT WITH
LEIDEN UNIVERSITY MEDICAL CENTRE FOR CLINICAL-STAGE LENTIVIRAL
GENE THERAPY WITH CURATIVE POTENTIAL FOR RAG1 SEVERE COMBINED
IMMUNODEFICIENCY
* MUSTANG BIO - EXECUTED EXCLUSIVE LICENSE AGREEMENT WITH
LEIDEN
UNIVERSITY MEDICAL CENTRE FOR EX VIVO LENTIVIRAL GENE THERAPY
FOR RAG1-SCID TREATMENT
* MUSTANG BIO INC - PRECLINICAL DEVELOPMENT OF ADDITIONAL
TARGETS
TO CONTINUE AT LEIDEN UNIVERSITY
Source text for Eikon: ID:nGNX9rppBc
Further company coverage: FBIO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mustang Bio
See all newsAdvisory: Alert on global oncology breakthroughs tagged to multiple pharma firms withdrawn
U.S. STOCKS ON THE MOVE-Dow, Phibro, Mustang Bio
Mustang soars on FDA's orphan drug tag for brain cancer therapy
Mustang Bio Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Mustang Bio Inc - Enters Sale And Surrender Agreement With Abbvie